Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Ralph Demasi"'
Autor:
Vani Vannappagari, Scott McCallister, Beth Romach, Mark Bush, Dinesh Stanislaus, Charlotte Root, Christine Lampkin, Nneka Nwokolo, Ana Puga, Sebastian Moreira, Farzaneh Salem, Ralph DeMasi, Nassrin Payvandi, Kimberly Smith, Harmony Garges, Annemiek de Ruiter
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 7, Pp 1391-1398 (2024)
Externí odkaz:
https://doaj.org/article/354bfc4390694dc7bdb524497eb31c46
Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
Publikováno v:
AIDS Research and Treatment, Vol 2015 (2015)
Background. An exploratory subanalysis of the ODIN trial was performed to evaluate the efficacy of darunavir/ritonavir (DRV/r) 800/100 mg OD versus 600/100 mg BID in patients who were NNRTI-experienced but PI-naïve. Methods. ODIN was a phase III, 48
Externí odkaz:
https://doaj.org/article/c90bebc0cfe747638d2893a8d0204b57
Autor:
Antonia Lepida, Massimo Colombo, Inmaculada Fernandez, Djamal Abdurakhmanov, Paulo Abrao Ferreira, Simone I Strasser, Petr Urbanek, Alessandra Mangia, José L Calleja, Wafae Iraqi, Ralph DeMasi, Isabelle Lonjon-Domanec, Christophe Moreno, Heiner Wedemeyer
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138503 (2015)
Liver stiffness determined by transient elastography is correlated with hepatic fibrosis stage and has high accuracy for detecting severe fibrosis and cirrhosis in chronic hepatitis C patients. We evaluated the clinical value of baseline FibroScan va
Externí odkaz:
https://doaj.org/article/07bb79088fac46afb6dfac475190cdde
Autor:
M Keith Rawlings, Emilio Letang, Romina Quercia, Richard Grove, Ralph DeMasi, Sherene Min, Vani Vannappagari, Andrew Zolopa, Jean van Wyk, Kimberly Smith
Publikováno v:
Open forum infectious diseases. 9(8)
Background In HIV clinical trials, proportions of Black and female participants achieving virologic suppression (VS) are often lower compared with White and male participants. As the antiretroviral therapy (ART) landscape continues to evolve, address
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c2af6718259d85aa79baa2e8d653461
https://pubmed.ncbi.nlm.nih.gov/36046700
https://pubmed.ncbi.nlm.nih.gov/36046700
Autor:
Chris Liu, Philip Bruggmann, Ralph DeMasi, Geert Robaeys, Sofia Keim, Graham R. Foster, Amber Arain, I. Lonjon-Domanec, Jan Kunkel, Damien Lucidarme, Martin Jäkel, Stefan Christensen
Publikováno v:
Infectious Diseases and Therapy
Introduction People who inject drugs represent an under-treated chronic hepatitis C virus (HCV)-infected patient population. Methods INTEGRATE was a prospective, observational study investigating the effectiveness, safety, and adherence in routine cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8b0d1c6e78d0d588e665219f3a4e19e
https://doi.org/10.1007/s40121-017-0158-x
https://doi.org/10.1007/s40121-017-0158-x
Autor:
Ashley Brown, Piero Luigi Almasio, Lawrence Serfaty, Suzanne Bourgeois, Giovanni Battista Gaeta, Peter Buggisch, Moisés Diago, Ramon Planas, Stefan Zeuzem, Ferenc Szalay, Edmund Omoruyi, I. Lonjon-Domanec, Christophe Hézode, M. Schlag, Y. Horsmans, Ralph DeMasi
Publikováno v:
Liver International. 37:1304-1313
Background & Aims: We investigated the efficacy and safety of simeprevir plus daclatasvir in treatment-naïve patients with chronic, genotype 1b hepatitis C virus infection and advanced liver disease, excluding patients with pre-defined NS5A resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ca4eb890ed244cc69f35759269c120b
https://doi.org/10.1111/liv.13376
https://doi.org/10.1111/liv.13376
Autor:
Stanislas Pol, I. Lonjon-Domanec, Thomas Berg, Stefan Zeuzem, Pietro Andreone, Graham R. Foster, Stuart K. Roberts, Moisés Diago, Andrzej Horban, Sandra De Meyer, Ralph DeMasi, R. Focaccia, Zobair M. Younossi, Donghan Luo, Gaston Picchio, Eric Lawitz
Publikováno v:
Liver International. 35:448-454
Background & Aims Predictors of response to treatment with peginterferon plus ribavirin are well established. In these post-hoc analyses of the REALIZE study, we sought to identify predictors of response for telaprevir-based triple therapy. Methods P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ccf7261c91185a927038fcd8eb20bac
https://doi.org/10.1111/liv.12703
https://doi.org/10.1111/liv.12703
Autor:
Chris Liu, Blanca Hadacek, Ralph DeMasi, Denes Banhegyi, Gabriella Verucchi, Colm Bergin, Andrea Gori, Manuela Doroana, Mark T. Nelson, Jürgen K. Rockstroh, Oksana Chernova
Publikováno v:
Journal of Infection. 71:675-682
Objectives: HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3595a04677ea0948cb88541c3393cb97
https://doi.org/10.1016/j.jinf.2015.09.013
https://doi.org/10.1016/j.jinf.2015.09.013
Autor:
Christopher I. Wright, Steven L. Flamm, Shelley George, Tara L. Kieffer, Natalie Bzowej, Andrew J. Muir, K. Rajender Reddy, David R. Nelson, Nathalie Adda, Geoffrey Dusheiko, Ralph DeMasi, Michael W. Fried, Leif Bengtsson, James C. Sullivan
Publikováno v:
Journal of Clinical Gastroenterology. 49:336-344
Background The phase 3 studies of telaprevir (T) in combination with peginterferon α-2a and ribavirin (PR) in treatment-naive genotype 1 chronic hepatitis C virus-infected patients (ADVANCE/ILLUMINATE) were not designed a priori to assess the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b57efcba94f65cffbf046e933d2a0530
https://doi.org/10.1097/mcg.0000000000000150
https://doi.org/10.1097/mcg.0000000000000150
Autor:
David M. Burger, Clara T. M. M. de Kanter, Anton S M Dofferhoff, Ralph DeMasi, James Witek, Joost P.H. Drenth, Maria Buti, Sivi Ouwerkerk-Mahadevan, Stefan Zeuzem
Publikováno v:
Antiviral Therapy, 21, 2, pp. 153-9
Antiviral Therapy, 21, 153-9
Antiviral Therapy, 21(2), 153. International Medical Press Ltd
Antiviral Therapy, 21, 153-9
Antiviral Therapy, 21(2), 153. International Medical Press Ltd
Background Monitoring ribavirin concentrations during hepatitis C treatment with dual therapy can help optimize treatment response and minimize anaemia. A defined therapeutic range for ribavirin during direct-acting antiviral-based therapies is lacki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42fd6282b1450120e7748014cb185bfa
https://doi.org/10.3851/imp2994
https://doi.org/10.3851/imp2994